Chapter 10 Exclude Nonqualified Research

Size: px
Start display at page:

Download "Chapter 10 Exclude Nonqualified Research"

Transcription

1 Chapter 10 Exclude Nonqualified Research 77

2 78 Research Tax Credits At this point, the taxpayer s research projects or cost-centers have been identified. Chapter 9 explained the four-part test and explained how to apply it to the projects or cost-centers to identify qualified and nonqualified research activities. The next step is to eliminate nonqualified research activities. There are several types of research activities that are nonqualified. These activities include research: Relating to style, taste, cosmetic, or seasonal design factors; Beginning after the start of commercial production; For adapting an existing business component; For certain surveys and studies; To reproduce existing products; To develop certain internal-use software; Not conducted in the U.S. or one if its possessions; In the social sciences, art, or humanities (literary, historical, or similar projects); and For services considered funded by a third-party. The rules for the research tax deduction contain similar exclusions. Because the research tax credit statute incorporates the research tax deduction as one of the four-part tests, the tax deduction limitations also apply for the research tax credit. Several of the limitations for the tax deduction are nearly identical to those for the tax credit. 1 They are also addressed in this chapter Style, Taste, Cosmetic, or Seasonal Design Factors Research activities related to style, taste, cosmetic, or seasonal design factors are not qualified. 2 This language seems to refer to activities that aim to improve the appearance of products. The treasury regulations provide an example in which a widget manufacturer paints several widgets a different color and surveys its customers to determine which widget they prefer. 3 The regulations conclude that this activity is not qualified because it relates to style, taste, cosmetic, or seasonal design factors. The Service also addressed this issue in Technical Advice Memorandum , in which a food manufacturer conducted research to improve the functional aspects of food products, such as developing new or improved textures, smells, and flavors. 4 The Service concluded that these activities were qualified. The Service reasoned that the word taste means individual or consumer preference and not sensory taste. This reasoning draws a distinction between making artistic improvements to the food products rather than the functional aspects of the food products. 1 The only limitation that is unique to the research tax deduction statute is the one that says that expenses for the acquisition of another s patent, model, production, or process are not research expenses. Treas. Reg (a)(3)(vi). These expenses would not qualify for the research tax credit because the expenses would not qualify as supply expenses. Supply expenses are expenses to acquire tangible property. I.R.C. 41(b)(2)(C). These intangible properties would not qualify as supply expenses. 2 I.R.C. 41(d)(3)(B). 3 Treas. Reg (a)(8)(ii). 4 T.A.M (Jun. 12, 1995).

3 Exclude Nonqualified Research 79 The Service has not provided any guidance on the term seasonal design. This broad term could be used to exclude research activities that clearly qualify for the research tax credit. For example, this term could be used to disqualify research activities to design a new tire, missile, or other product that functions in harsh winter or summer weather. 5 As with the term taste, a more appropriate interpretation would focus on the word design in the artistic, rather than the functional sense After the Start of Production Research activities performed after the start of commercial production are not qualified. 6 Commercial production starts when the business component is developed to the point that it meets the basic functional and economic requirements of the taxpayer for the component s sale or use. 7 This is the point at which the taxpayer has developed a product, prototype, or process that could be sold or used in the taxpayer s business in the ordinary course of its business. 8 The regulations say that the following activities are deemed to occur after the beginning of commercial production of a business component: Preproduction planning for a finished business component; Tooling-up for production; Trial production runs; Trouble shooting involving detecting faults in production equipment or processes; Accumulating data relating to production processes; and Debugging flaws in a business component. 9 As depicted in Figure 10.01, the typical steps in the research and manufacturing process include inception, preliminary evaluation, development of data for design, economic evaluation, engineering design, procurement, assembly, startup and trial runs, and production. 10 The inception, preliminary evaluation, development of data for design, economic evaluation, and engineering design steps come before the start of commercial production. They can qualify as research. 11 However, the tasks described as procurement, assembly, start-up and trial runs, and production are considered to be at or after the start of commercial production. They generally do not qualify as research Treas. Reg (c)(10), Ex. (1). 6 I.R.C. 41(d)(4)(A). 7 Treas. Reg (c)(2). 8 T.A.M (Apr. 22, 1988) (finding that the taxpayer s product was not ready for commercial production even though the taxpayer had installed the product at its headquarters and on its customer s sites because the installation was part of the process in designing the product). 9 Treas. Reg (c)(2)(ii). 10 See generally I.L.M F (Apr. 27, 2007); F.S.A (Mar. 31, 2000). 11 See I.L.M F (Apr. 27, 2007) (finding that assembly activities take place after the start of commercial production). 12 F.S.A (Mar. 31, 2000) (finding that research ended when the initial products were produced, not when the manufacturing process is brought to the level of producing the proper volume of products).

4 80 Research Tax Credits These steps can vary from taxpayer to taxpayer and from industry to industry. For example, the pharmaceutical drug development process is composed of four stages, namely, preclinical or discovery research, clinical development, regulatory approval, and post marketing. 13 The preclinical or discovery and clinical development steps generally qualify; whereas, the regulatory approval and post marketing steps generally do not. Figure The treasury regulations include several examples that explain these concepts. In one example, the taxpayer designs and manufactures a new belt to be used in its manufacturing equipment. 14 The design and testing activities qualify. 15 The activities to manufacture, install, and test the belts do not qualify because they occurred after the belts met the taxpayer s functional and economic requirements. 16 In another example, a taxpayer produces various types of widgets. 17 It decides to design a new type of widget. The activities to design the new widget are not after the start of commercial production simply because the taxpayer had previously designed and manufactured other types of widgets Memorandum from Henry v. Singleton, Emerging Issue Alert on the Property Treatment of Non-Refundable Upfront Fees, Technology Access Fees, Milestone Payments, Royalties and Deferred Income under a Collaboration Agreement in the Pharmaceutical and Biotech Industries, (Jul. 7, 2005), available at (last visited May 15, 2011). 14 Treas. Reg (c)(10), Ex. (1) Treas. Reg (c)(10), Ex. (2). 18

5 Exclude Nonqualified Research 81 The regulations also include special rules for clinical testing of pharmaceutical products. 19 These rules say that clinical testing of a pharmaceutical product prior to its commercial production in the United States is not treated as occurring after the beginning of commercial production even if the product is commercially available in other countries. They also say that additional clinical testing of a pharmaceutical product after a product has been approved for a specific therapeutic use by the Food and Drug Administration (FDA) and is ready for commercial production and sale is not treated as occurring after the beginning of commercial production if such clinical testing is undertaken to establish new functional uses, characteristics, indications, combinations, dosages, or delivery forms for the product. The regulations define a functional use, characteristic, indication, combination, dosage, or delivery form as new only if it must be approved by the FDA. This limitation can be difficult to apply if the business component is a process improvement rather than a product or service. Specifically, a taxpayer who manufactures products or provides services will usually already have a process in place to manufacture the product or provide the service. Activities to design a new manufacturing process or process to provide a service qualify as process improvements, independent of the research for the underlying product or service Adapting an Existing Business Component Research activities used to adapt existing business components to customer requirements or needs are not qualified. 20 This rule does not apply merely because a business component is intended for a specific customer. 21 Also, this rule does not apply if the taxpayer builds a new business component that satisfies a customer s requirement. The regulations include an example for this rule. 22 In the example, the taxpayer is in the business of licensing computer software. It performs research to adapt the existing software to fit a customer s need. The regulations conclude that the research activities are to adapt an existing business component because the business component, the computer software, already exists and the taxpayer merely modifies it to fit the customer s need. This prevents this type of activity from qualifying. The regulations include another example whereby a rail car manufacturer designs a rail car. 23 The car is similar to the cars ordered by its other customers except for having fewer seats in the passenger cars and a higher quality seating material and carpet that are commercially available. The regulations conclude that the car was merely an adaptation of an existing business component, rather than a new business component. The regulations include yet another example in which a taxpayer purchases existing robotic equipment to modify to fit its own existing needs. 24 The taxpayer is uncertain as to how to modify 19 Treas. Reg (c)(2)(iv). 20 I.R.C. 41(d)(4)(B); Treas. Reg (c)(3). 21 Treas. Reg (c)(3). 22 Treas. Reg (c)(10), Ex. (2)(ii). 23 Treas. Reg (c)(10), Ex Treas. Reg (c)(10), Ex. 7.

22 Federal Register / Vol. 69, No. 1 / Friday, January 2, 2004 / Rules and Regulations

22 Federal Register / Vol. 69, No. 1 / Friday, January 2, 2004 / Rules and Regulations 22 Federal Register / Vol. 69, No. 1 / Friday, January 2, 2004 / Rules and Regulations change within two years after the effective date of the statute. The statute provides specific procedures to establish

More information

[COMPANY NAME] Research & Development Tax Credit Assessment n For tax year ended December 31, 20xx

[COMPANY NAME] Research & Development Tax Credit Assessment n For tax year ended December 31, 20xx [COMPANY NAME] Research & Development Tax Credit Assessment n For tax year ended December 31, 20xx Prepared for ABC Manufacturing, Inc. Estimate for the Tax Year Ended December 31, 2015 Any tax advice

More information

Table of contents. This section lists the table of contents for through

Table of contents. This section lists the table of contents for through Code of Federal Regulations -- Title 26: Internal Revenue -- Chapter 1: Internal Revenue Service, Department of the Treasury-- Subchapter A: Income Tax -- Part 1: Income Taxes -- Section 1.41: Credit for

More information

Aerospace Industry - Audit Techniques Guide - January 2005

Aerospace Industry - Audit Techniques Guide - January 2005 Aerospace Industry - Audit Techniques Guide - January 2005 NOTE: This guide is current through the publication date. Since changes may have occurred after the publication date that would affect the accuracy

More information

BEFORE WE GET STARTED

BEFORE WE GET STARTED SOLUTIONS FOR TAX PROFESSIONALS AND BUSINESSES TAX CREDITS INCENTIVES COST RECOVERY BEFORE WE GET STARTED Welcome and thank you for joining KBKG s live webinar We will start the live webinar at 12pm PT

More information

Coordinated Issue All Industries Research Tax Credit - Internal Use Software (Effective Date: August 26, 1999)

Coordinated Issue All Industries Research Tax Credit - Internal Use Software (Effective Date: August 26, 1999) Coordinated Issue All Industries Research Tax Credit - Internal Use Software (Effective Date: August 26, 1999) UIL 41.51-10 ISSUE Effective Date: August 26, 1999 Are X's activities related to the installation,

More information

Revenue from contracts with customers The standard is final A comprehensive look at the new revenue model

Revenue from contracts with customers The standard is final A comprehensive look at the new revenue model What s inside: Overview... 1 Scope...2 Licences and rights to use...2 Variable consideration and the constraint on revenue recognition...5 Sales to distributors and consignment stock...10 Collaborations

More information

24 th Annual Health Sciences Tax Conference

24 th Annual Health Sciences Tax Conference 24 th Annual Health Sciences Tax Conference Understanding the tax impact of joint ventures and December 10, 2014 Disclaimer EY refers to the global organization, and may refer to one or more, of the member

More information

TECHNICAL EXPLANATION OF THE INNOVATION PROMOTION ACT OF 2015

TECHNICAL EXPLANATION OF THE INNOVATION PROMOTION ACT OF 2015 TECHNICAL EXPLANATION OF THE INNOVATION PROMOTION ACT OF 2015 July 28, 2015 CONTENTS Page A. Deduction for Innovation Box Profits... 1 B. Special Rules for Transfers of Intangible Property From Controlled

More information

Accounting Standards Update (ASU) No , Revenue from Contracts with Customers (Topic 606), issued by FASB. 2

Accounting Standards Update (ASU) No , Revenue from Contracts with Customers (Topic 606), issued by FASB. 2 Executive Summary When the Financial Accounting Standards Board (FASB) announced new financial accounting standards for recognizing revenue (herein referenced as ASC 606 ) 1 in May 2014 to replace existing

More information

Tax Issues in Clinical Research

Tax Issues in Clinical Research Tax Issues in Clinical Research AHLA October 2013 Ann Hollenbeck Bob Waitkus 1 Tax Issues in Clinical Research Three Topics: 1. Clinical Research: related to mission and UBTI issues 2. Private Use Issues:

More information

S Corporation Shareholder Basis. Losses Claimed in Excess of Basis

S Corporation Shareholder Basis. Losses Claimed in Excess of Basis S Corporation Shareholder Basis Losses Claimed in Excess of Basis Campaign Description S corporation shareholders must track adjustments to their basis in S corporation stock and debt to avoid improperly

More information

Agenda Item 3(a)(v): Article 12 (Royalties)

Agenda Item 3(a)(v): Article 12 (Royalties) Committee of Experts on International Cooperation in Tax Matters 11 th Session: Geneva, 19-23 October 2015 Agenda Item 3(a)(v): Article 12 (Royalties) a) The meaning of industrial, commercial and scientific

More information

Life Sciences Accounting and Financial Reporting Update Interpretive Guidance on Revenue Recognition Under ASC 606

Life Sciences Accounting and Financial Reporting Update Interpretive Guidance on Revenue Recognition Under ASC 606 Life Sciences Accounting and Financial Reporting Update Interpretive Guidance on Revenue Recognition Under ASC 606 March 2017 Revenue Recognition Background In May 2014, the FASB 1 and IASB issued their

More information

IFRS 15 for automotive suppliers

IFRS 15 for automotive suppliers IFRS 15 for automotive suppliers Are you good to go? Application guidance December 2017 Contents Contents Purpose of this document 1 What may change? 2 1 Tender offer phase Nomination fees 4 2 Framework

More information

Research and Development Tax Credit

Research and Development Tax Credit Research and Development Tax Credit Tax savings for companies involved with innovative new or improved products or processes Prepared by: Matthias Needam, Director CSG Strategic Tax Consultants Abstract

More information

Monetary figures in the financial statements are expressed in millions of euros unless otherwise stated.

Monetary figures in the financial statements are expressed in millions of euros unless otherwise stated. Notes to the consolidated financial statements General information Orion Corporation is a Finnish public limited liability company domiciled in Espoo, Finland, and registered at Orionintie 1, FI-02200

More information

Revenue Recognition: A Comprehensive Look at the New Standard

Revenue Recognition: A Comprehensive Look at the New Standard Revenue Recognition: A Comprehensive Look at the New Standard BACKGROUND & SUMMARY... 3 SCOPE... 4 COLLABORATIVE ARRANGEMENTS... 4 THE REVENUE RECOGNITION MODEL... 5 STEP 1 IDENTIFY THE CONTRACT WITH A

More information

By Brian McCuller, JD, CPA, and Andrew Hill, JD

By Brian McCuller, JD, CPA, and Andrew Hill, JD Impact of the PATH ACT and Other Business Legislation By Brian McCuller, JD, CPA, and Andrew Hill, JD The dust has settled on 2015 s state and federal tax legislation. There is much welcome news for Tennessee

More information

International Income Taxation Chapter 12: EXPLOITATION OF INTANGIBLES

International Income Taxation Chapter 12: EXPLOITATION OF INTANGIBLES Presentation: International Income Taxation Chapter 12: EXPLOITATION OF INTANGIBLES Professors Wells April 16, 2018 Chapter 12 Exploiting Intangibles Outside U.S. Choices for structuring these arrangements:

More information

Will the IRS Deny MACRS Depreciation for Your Aircraft Based on Your Business Organizational Chart? -By Troy A. Rolf-

Will the IRS Deny MACRS Depreciation for Your Aircraft Based on Your Business Organizational Chart? -By Troy A. Rolf- Will the IRS Deny MACRS Depreciation for Your Aircraft Based on Your Business Organizational Chart? -By Troy A. Rolf- GKG Law, P.C. 1054 Thirty-First Street, N.W. Washington, D.C. 20007 Phone: (202) 342-5200

More information

Imugene to Raise A$20.1 million

Imugene to Raise A$20.1 million Not for release to US wire services or distribution in the United States ASX Announcement Imugene to Raise A$20.1 million License of US based B-cell cancer vaccine platform creating a dominant position

More information

Section Income Attributable to Domestic Production Activities

Section Income Attributable to Domestic Production Activities Part III - Administrative, Procedural, and Miscellaneous Section 199.--Income Attributable to Domestic Production Activities Notice 2005-14 CONTENTS SECTION 1. PURPOSE SECTION 2. OVERVIEW OF 199.01 In

More information

Temporary rules under section 6662A and sections 6662 and 6664, as amended

Temporary rules under section 6662A and sections 6662 and 6664, as amended Part III - Administrative, Procedural, and Miscellaneous Temporary rules under section 6662A and sections 6662 and 6664, as amended Notice 2005-12 The purpose of this notice is to alert taxpayers to the

More information

Chapter 12 - Exploiting Intangibles Outside U.S.

Chapter 12 - Exploiting Intangibles Outside U.S. Chapter 12 - Exploiting Intangibles Outside U.S. Choices for structuring these arrangements: 1) Independent licensing for royalties. 2) Transfer of intangible property rights in an independent capital

More information

Adopting the R&D Credit Payroll Tax Offset OR Fostering the Orphan Drug Credit?

Adopting the R&D Credit Payroll Tax Offset OR Fostering the Orphan Drug Credit? Adopting the R&D Credit Payroll Tax Offset OR Fostering the Orphan Drug Credit? A NEW Consideration for Startup Pharma s Kathleen Milone, CPA Abstract: Due to recently enacted legislation, startup pharmaceutical

More information

SPECIAL REPORT. tax notes. IRS Assumes Away Inconvenient Law in Reinsurance CCA. By William R. Pauls

SPECIAL REPORT. tax notes. IRS Assumes Away Inconvenient Law in Reinsurance CCA. By William R. Pauls IRS Assumes Away Inconvenient Law in CCA By William R. Pauls William R. Pauls is a partner in the Washington office of Sutherland Asbill & Brennan LLP. He gratefully acknowledges Michael Miles, a partner

More information

International Income Taxation Chapter 12: EXPLOITATION OF INTANGIBLES

International Income Taxation Chapter 12: EXPLOITATION OF INTANGIBLES Presentation: International Income Taxation Chapter 12: EXPLOITATION OF INTANGIBLES Professors Wells April 20, 2016 Chapter 12 Exploiting Intangibles Outside U.S. Choices for structuring these arrangements:

More information

FASB Emerging Issues Task Force

FASB Emerging Issues Task Force EITF Issue No. 08-9 FASB Emerging Issues Task Force Issue No. 08-9 Title: Milestone Method of Revenue Recogntion Document: Issue Summary No. 1 Date prepared: October 20, 2008 FASB Staff: Maples (ext. 462)/Elsbree

More information

CHAPTER House Bill No. 415

CHAPTER House Bill No. 415 CHAPTER 2006-57 House Bill No. 415 An act relating to the tax on sales, use, and other transactions; amending s. 212.052, F.S.; deleting an exception to an exemption from the tax for research or development

More information

Isotechnika Pharma Inc. Consolidated Financial Statements December 31, 2012 and 2011

Isotechnika Pharma Inc. Consolidated Financial Statements December 31, 2012 and 2011 Consolidated Financial Statements December 31, 2012 and 2011 MANAGEMENT S RESPONSIBILITY FOR FINANCIAL REPORTING The accompanying consolidated financial statements of Isotechnika Pharma Inc. are the responsibility

More information

Lending in the United States by Foreign Person Giving Rise to Effectively Connected Income

Lending in the United States by Foreign Person Giving Rise to Effectively Connected Income Office of Chief Counsel Internal Revenue Service Memorandum Number: Release Date: CC:INTL:BR5 PRENO-119800-09 Third Party Communication: None Date of Communication: Not Applicable UILC: 864.02-00 date:

More information

March 29, kpmg.com

March 29, kpmg.com U.S. tax reform Planning in uncertain times Forward-thinking life sciences companies may want to consider the impact of potential tax reform on their supply chain, R&D, and more March 29, 2017 In light

More information

ALMIRALL, S.A. and Subsidiaries (Almirall Group)

ALMIRALL, S.A. and Subsidiaries (Almirall Group) and Subsidiaries (Almirall Group) Consolidated annual accounts for the year ended, prepared in accordance with International Financial Reporting Standards (IFRS) adopted by the European Union (Translation

More information

Interim Report, First Quarter 2014

Interim Report, First Quarter 2014 Interim Report, First Quarter 2014 CORTENDO REPORTS RESULTS AND ACTIVITIES FOR THE FIRST QUARTER 2014 FIRST AND POST QUARTER HIGHLIGHTS Continued progress on the start-up of NormoCort Phase 3 trial While

More information

LUPIN INC. AND SUBSIDIARIES. Consolidated Financial Statements As of and for the Years Ended March 31, 2018 and 2017

LUPIN INC. AND SUBSIDIARIES. Consolidated Financial Statements As of and for the Years Ended March 31, 2018 and 2017 LUPIN INC. AND SUBSIDIARIES Consolidated Financial Statements As of and for the Years Ended March 31, 2018 and 2017 TABLE OF CONTENTS Page Independent Auditor s Report 1 Consolidated Balance Sheets 2 Consolidated

More information

Management s Discussion and Analysis of Financial Condition and Results of Operations of Profound Medical Corp. for the Year Ended December 31, 2015

Management s Discussion and Analysis of Financial Condition and Results of Operations of Profound Medical Corp. for the Year Ended December 31, 2015 Management s Discussion and Analysis of Financial Condition and Results of Operations of Profound Medical Corp. for the Year Ended December 31, 2015 The following Management s Discussion and Analysis (

More information

Un-audited Condensed Consolidated Interim Financial Statements of. InMed Pharmaceuticals Inc. For the Three Months Ended September 30, 2018

Un-audited Condensed Consolidated Interim Financial Statements of. InMed Pharmaceuticals Inc. For the Three Months Ended September 30, 2018 Un-audited Condensed Consolidated Interim Financial Statements of InMed Pharmaceuticals Inc. For the Three Months Ended September 30, 2018 Suite 340 200 Granville Street Vancouver, BC, Canada, V6C 1S4

More information

Tax Executives Institute Houston Chapter TS1806. March 1, 2018

Tax Executives Institute Houston Chapter TS1806. March 1, 2018 Tax Executives Institute Houston Chapter TS1806 March 1, 2018 Federal research deduction ( 174), credit ( 41) and state research credits before and after reform Page 1 Speakers David Hudson, National Tax

More information

Life Sciences Accounting and Financial Reporting Update Interpretive Guidance on Consolidation

Life Sciences Accounting and Financial Reporting Update Interpretive Guidance on Consolidation Life Sciences Accounting and Financial Reporting Update Interpretive Guidance on Consolidation March 2017 Consolidation Introduction Life sciences entities enter into a variety of arrangements with other

More information

Current Developments New GAAP Requirements and Effect on Accounting for Income Taxes

Current Developments New GAAP Requirements and Effect on Accounting for Income Taxes Current Developments New GAAP Requirements and Effect on Accounting for Income Taxes Greg Pfahl/John Monahan December 8, 2016 New Revenue Recognition Standard Replacing industry-specific guidance, the

More information

FASB Emerging Issues Task Force

FASB Emerging Issues Task Force EITF Issue No. 07-1 FASB Emerging Issues Task Force Issue No. 07-1 Title: Accounting for Collaborative Arrangements Related to the Development and Commercialization of Intellectual Property Document: Issue

More information

Transition Resource Group for Revenue Recognition Sales-Based or Usage-Based Royalty with Minimum Guarantee.

Transition Resource Group for Revenue Recognition Sales-Based or Usage-Based Royalty with Minimum Guarantee. TRG Agenda ref 58 STAFF PAPER November 7, 2016 Project Paper topic Transition Resource Group for Revenue Recognition Sales-Based or Usage-Based Royalty with Minimum Guarantee CONTACT(S) Dan Drobac ddrobac@fasb.org

More information

Combined Financial Statements (UNAUDITED) NATIONAL MULTIPLE SCLEROSIS SOCIETY NATIONAL HEADQUARTERS, FAST FORWARD AND CHAPTERS

Combined Financial Statements (UNAUDITED) NATIONAL MULTIPLE SCLEROSIS SOCIETY NATIONAL HEADQUARTERS, FAST FORWARD AND CHAPTERS Combined Financial Statements (UNAUDITED) NATIONAL MULTIPLE SCLEROSIS SOCIETY NATIONAL HEADQUARTERS, FAST FORWARD AND CHAPTERS UNAUDITED Page 1 National Headquarters, Fast Forward and Chapters TABLE OF

More information

BEFORE THE ARIZONA DEPARTMENT OF REVENUE. In the Matter of ) DECISION OF ) HEARING OFFICER [REDACTED] ) ) Case No C I.D. No.

BEFORE THE ARIZONA DEPARTMENT OF REVENUE. In the Matter of ) DECISION OF ) HEARING OFFICER [REDACTED] ) ) Case No C I.D. No. BEFORE THE ARIZONA DEPARTMENT OF REVENUE In the Matter of ) DECISION OF ) HEARING OFFICER [REDACTED] ) ) Case No. 201200235-C I.D. No. [REDACTED] ) ) A hearing was held on February 12, 2013 in the matter

More information

The new revenue recognition standard - software and cloud services

The new revenue recognition standard - software and cloud services Applying IFRS in Software and Cloud Services The new revenue recognition standard - software and cloud services January 2015 Overview Software entities may need to change their revenue recognition policies

More information

At your request, we have researched whether client American Beef Conglomerate, Inc.

At your request, we have researched whether client American Beef Conglomerate, Inc. MEMORANDUM TO: Senior Partner FROM: LL.M. Team Number DATE: November 6, 2015 SUBJECT: 2015-2016 Law Student Tax Challenge Problem At your request, we have researched whether client American Beef Conglomerate,

More information

Capital Gains Exclusion for Small Business Stock Held for More Than 5 Years. By Stephen D. D. Hamilton, July 2011

Capital Gains Exclusion for Small Business Stock Held for More Than 5 Years. By Stephen D. D. Hamilton, July 2011 Capital Gains Exclusion for Small Business Stock Held for More Than 5 Years I. Background. By Stephen D. D. Hamilton, July 2011 A. Enactment of exemption. The Creating Small Business Jobs Act of 2010,

More information

FY11. Financial Results T.HASEGAWA T.HASEGAWA CO., LTD. R&D Center

FY11. Financial Results T.HASEGAWA T.HASEGAWA CO., LTD. R&D Center FY11 Financial Results T.HASEGAWA CO., LTD. R&D Center 1 Caution with Respect to Forward-Looking Statements: This material contains forward-looking statements about the future performance of T. Hasegawa,

More information

Applying IFRS. IASB proposed standard. Revenue from contracts with customers the revised proposal

Applying IFRS. IASB proposed standard. Revenue from contracts with customers the revised proposal Applying IFRS IASB proposed standard Revenue from contracts with customers the revised proposal January 2012 Overview What you need to know The IASB and the FASB have issued a second exposure draft of

More information

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS of Financial Condition and Results of Operations of Profound Medical Corp. for the Three and Six Months Ended June 30, 2017 The following ( MD&A ) prepared as of August 24, 2017 should be read in conjunction

More information

ANALYZING CHARACTERISTICS OF DESIGN BUILD DELIVERY SYSTEM IN KOREA

ANALYZING CHARACTERISTICS OF DESIGN BUILD DELIVERY SYSTEM IN KOREA 24th International Symposium on on Automation & Robotics in in Construction (ISARC 2007) Construction Automation Group, I.I.T. Madras ANALYZING CHARACTERISTICS OF DESIGN BUILD DELIVERY SYSTEM IN KOREA

More information

WuXi Biologics 2017 Interim Results

WuXi Biologics 2017 Interim Results WuXi Biologics 2017 Interim Results August 2017 (Stock Code: 2269.HK) Forward-Looking Statements This presentation may contain certain forward-looking statements are not historical facts, but instead are

More information

Technical Line FASB final guidance

Technical Line FASB final guidance No. 2017-22 Updated 4 December 2017 Technical Line FASB final guidance How the new revenue standard affects life sciences entities In this issue: Overview... 1 Collaborative arrangements... 2 Effect of

More information

B.6. Cost Contribution Arrangements

B.6. Cost Contribution Arrangements B.6. Cost Contribution Arrangements Introduction B.6.1. This chapter provides guidance on the use of cost contribution arrangements (CCAs) and the application of the arm s length principle to CCAs for

More information

How the New Tax Law Impacts Hollywood: Lights, Camera, Accelerated Deduction! 1. Shane Nix, Esq.

How the New Tax Law Impacts Hollywood: Lights, Camera, Accelerated Deduction! 1. Shane Nix, Esq. How the New Tax Law Impacts Hollywood: Lights, Camera, Accelerated Deduction! 1 Shane Nix, Esq. Costs for film and television productions generally are required to be capitalized and added to the tax basis

More information

Pharming Group NV (OTC: PHGUF) PHARM.AS AEX Buy

Pharming Group NV (OTC: PHGUF) PHARM.AS AEX Buy Scott R. Henry, CFA, (949) 720-7123 shenry@roth.com Sales (800) 933-6830, Trading (800) 933-6820 Healthcare: BioPharmaceuticals COMPANY NOTE EQUITY RESEARCH May 18, 2017 Pharming Group NV (OTC: PHGUF)

More information

Inbound Transactions: Withholding and Reporting

Inbound Transactions: Withholding and Reporting Chapter 78 Inbound Transactions: Withholding and Reporting 78:1 Carryovers: Mergers and Acquisitions 78:1.1 Hovering Deficit Rule 78:1.2 Section 361 Exchanges 78:1.3 Section 351 Exchanges [A] Exception

More information

International Financial Reporting Standards (IFRS) Issues and Solutions for the Pharmaceuticals and Life Sciences Industries - Vol III

International Financial Reporting Standards (IFRS) Issues and Solutions for the Pharmaceuticals and Life Sciences Industries - Vol III Pharmaceuticals and Life Sciences International Financial Reporting Standards (IFRS) Issues and Solutions for the Pharmaceuticals and Life Sciences Industries - Vol III Accounting For Licensing and Development

More information

Recent Developments in Tax Accounting. Dwight Mersereau

Recent Developments in Tax Accounting. Dwight Mersereau Recent Developments in Tax Accounting Dwight Mersereau Agenda Revised Accounting Method Change Procedures Expense Recognition Fines & Penalties Section 199 Update on Tangible Property Regulations 1 Revised

More information

S Corporation Shareholder Stock Basis & Bona Fide Shareholder Debt

S Corporation Shareholder Stock Basis & Bona Fide Shareholder Debt S Corporation Shareholder Stock Basis & Bona Fide Shareholder Debt Shareholder Debt Basis IRC 1366(d)(1)(B) states that losses are allowed up to the amount of the shareholder's adjusted basis of any indebtedness

More information

Gifts of Intellectual Property. David Wheeler Newman

Gifts of Intellectual Property. David Wheeler Newman Gifts of Intellectual Property David Wheeler Newman The democratization of technology means that more people are able to create and transfer intellectual property, including patents, trademarks and copyrights,

More information

Interim report January March 2009

Interim report January March 2009 Interim report January March 2009 Vitrolife AB (publ) Strong conclusion to a record quarter Sales increased by 22 percent to SEK 71.8 (58.7) million. Calculated in local currencies growth was 4 percent.

More information

FASB/IASB Joint Transition Resource Group for Revenue Recognition Application of the Series Provision and Allocation of Variable Consideration

FASB/IASB Joint Transition Resource Group for Revenue Recognition Application of the Series Provision and Allocation of Variable Consideration TRG Agenda ref 39 STAFF PAPER Project Paper topic July 13, 2015 FASB/IASB Joint Transition Resource Group for Revenue Recognition Application of the Series Provision and Allocation of Variable Consideration

More information

Table of content. Kuros Biosciences 2017 Interim Report 1

Table of content. Kuros Biosciences 2017 Interim Report 1 Interim Report 2017 Table of content Financial performance and results of operations... 3 Consolidated balance sheets... 4 Consolidated income statements... 5 Consolidated statements of comprehensive income...

More information

FINANCIAL CONFLICT OF INTEREST POLICY

FINANCIAL CONFLICT OF INTEREST POLICY FINANCIAL CONFLICT OF INTEREST POLICY Individuals who are appointed to serve on ABIM boards or committees are expected to have the American Board of Internal Medicine s (ABIM) mission as their primary

More information

Research Tax Credit: Basic Concepts Steve Pashley, CPA, LL.M.

Research Tax Credit: Basic Concepts Steve Pashley, CPA, LL.M. Research Tax Credit: Basic Concepts Steve Pashley, CPA, LL.M. Senior Manager, Credits and Incentives November 10, 2015 Topics covered 1. Learning objectives 2. The IRC section 41 research tax credit 3.

More information

Intellectual Property Policy

Intellectual Property Policy Intellectual Property Policy For Partners-Affiliated Hospitals and Institutions The Hospitals and other Institutions affiliated with Partners HealthCare System are not-for-profit corporations which share

More information

A shift in the top line

A shift in the top line A shift in the top line A new global standard on accounting for revenue The FASB, along with the IASB, has finally issued ASU 2014-09, Revenue from Contracts with Customers, its new standard on revenue.

More information

Life Sciences Accounting and Financial Reporting Update Interpretive Guidance on Research and Development

Life Sciences Accounting and Financial Reporting Update Interpretive Guidance on Research and Development Life Sciences Accounting and Financial Reporting Update Interpretive Guidance on Research and Development March 2018 Research and Development Introduction New product development in the life sciences industry

More information

Claiming Scientific Research and Experimental Development

Claiming Scientific Research and Experimental Development Claiming Scientific Research and Experimental Development Guide to Form T661 T4088(E) Rev. 03 Blind or visually impaired persons can get this publication in braille and large print, and on audio cassette

More information

Financial Report FIRST QUARTER

Financial Report FIRST QUARTER Financial Report 20 FIRST QUARTER 19 The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more

More information

CONSOLIDATED FINANCIAL STATEMENTS These Consolidated Financial Statements were publicly released in the Japanese language on November 9, 2016.

CONSOLIDATED FINANCIAL STATEMENTS These Consolidated Financial Statements were publicly released in the Japanese language on November 9, 2016. CONSOLIDATED FINANCIAL STATEMENTS These Consolidated Financial Statements were publicly released in the Japanese language on November 9, 2016. (1)Consolidated balance sheet 2016/3/31 2016/9/30 Assets Current

More information

CFC income from software leases determined to be foreign personal holding company income

CFC income from software leases determined to be foreign personal holding company income 18 July 2013 CFC income from software leases determined to be foreign personal holding company income Executive summary On 15 July 2013, the Internal Revenue Service (the Service) released Field Attorney

More information

FASB Emerging Issues Task Force. Issue No Title: Research and Development Assets Acquired In an Asset Acquisition

FASB Emerging Issues Task Force. Issue No Title: Research and Development Assets Acquired In an Asset Acquisition EITF Issue No. 09-2 FASB Emerging Issues Task Force Issue No. 09-2 Title: Research and Development Assets Acquired In an Asset Acquisition Document: Issue Summary No. 1, Issue Supplement No. 1 Date prepared:

More information

eskbook Emerging Life Sciences Companies second edition

eskbook Emerging Life Sciences Companies second edition eskbook Emerging Life Sciences Companies second edition Chapter 36 Expanding to the United States: Issues for a Biotech Company to Consider in Preparing for a U.S. Market Entry Chapter 36 EXPANDING TO

More information

Sareum Holdings plc. Paper on lead candidate CHK1 published in high-impact journal. Update. 23 July 2015 HYBRIDAN LLP

Sareum Holdings plc. Paper on lead candidate CHK1 published in high-impact journal. Update. 23 July 2015 HYBRIDAN LLP Update 23 July 2015 Key Statistics Code : SAR Listing : AIM Sector : Pharmaceuticals & Biotech Market Cap FD : 6m Shares in issue FD : 2,487.4m Current Price : 0.245 12 mnth High/Low : 0.6p/0.205p Stock

More information

CHARITABLE CONTRIBUTIONS OF APPRECIATED PROPERTY

CHARITABLE CONTRIBUTIONS OF APPRECIATED PROPERTY CHARITABLE CONTRIBUTIONS OF APPRECIATED PROPERTY Publication CHARITABLE CONTRIBUTIONS OF APPRECIATED PROPERTY December 14, 2011 The holiday season is a particularly good time for many individuals to consider

More information

LIFE SCIENCE PRODUCT SHORTAGE COVERAGE ENDORSEMENT SCHEDULE. Coverage Limit Of Insurance Deductible or Retention. $ aggregate

LIFE SCIENCE PRODUCT SHORTAGE COVERAGE ENDORSEMENT SCHEDULE. Coverage Limit Of Insurance Deductible or Retention. $ aggregate LIFE SCIENCE PRODUCT SHORTAGE COVERAGE ENDORSEMENT This endorsement modifies insurance provided under the following: LIFE SCIENCES LIABILITY POLICY SCHEDULE Coverage Limit Of Insurance Deductible or Retention

More information

Novel Laboratories, Inc. Financial Statements As of and For the Year Ended March 31, 2017

Novel Laboratories, Inc. Financial Statements As of and For the Year Ended March 31, 2017 Novel Laboratories, Inc. Financial Statements As of and For the Year Ended TABLE OF CONTENTS Page Independent Auditors Report 1 Balance Sheet 2 Statement of Operations 3 Statement of Changes in Stockholder

More information

Comment on the Exposure Draft ED/2010/6 Revenue from Contracts with Customers

Comment on the Exposure Draft ED/2010/6 Revenue from Contracts with Customers 22 October 2010 International Accounting Standards Board 30 Cannon Street London EC4M 6XH United Kingdom Dear Sir or Madame, Comment on the Exposure Draft ED/2010/6 Revenue from Contracts with Customers

More information

(Text with EEA relevance)

(Text with EEA relevance) 29.10.2016 L 295/19 COMMISSION REGULATION (EU) 2016/1905 of 22 September 2016 amending Regulation (EC) No 1126/2008 adopting certain international accounting standards in accordance with Regulation (EC)

More information

State & Local Tax Alert

State & Local Tax Alert State & Local Tax Alert Breaking state and local tax developments from Grant Thornton LLP New Jersey Tax Court Finds Payments Made by Subsidiary Qualify for Exception to Addback Rule On May 24, 2017, the

More information

Photocure ASA - Third Quarter Report 2008

Photocure ASA - Third Quarter Report 2008 Photocure ASA - Third Quarter Report 2008 Highlights Sales revenues increase 52% to NOK 23.6 million ( from NOK 15.6 million in third quarter 2007) Operating profit improved by NOK 13.7 million to NOK

More information

DR. DAVID MATHUVA STRATHMORE BUSINESS SCHOOL FINANCIAL MANAGEMENT WORKSHOP FOR SMES

DR. DAVID MATHUVA STRATHMORE BUSINESS SCHOOL FINANCIAL MANAGEMENT WORKSHOP FOR SMES 1 REVENUE IN SMEs DR. DAVID MATHUVA STRATHMORE BUSINESS SCHOOL FINANCIAL MANAGEMENT WORKSHOP FOR SMES 2 Many SMEs pursue optimization of taxable profit (i.e., minimizing taxes) Do you agree? 3 What is

More information

NASCIO Internet Counter Report (ICR) Award Submission Executive Summary

NASCIO Internet Counter Report (ICR) Award Submission Executive Summary NASCIO Internet Counter Report (ICR) Award Submission Executive Summary https:/crash.state.co.us Colorado s high mountain passes and wide-open plains often produce unexpected severe weather that causes

More information

24 th Annual Health Sciences Tax Conference

24 th Annual Health Sciences Tax Conference 24 th Annual Health Sciences Tax Conference What s shaking? State and local tax hot topics for the life sciences industry December 8, 2014 Disclaimer EY refers to the global organization, and may refer

More information

Dealdoc. IPO for $49.5 million. Horizon Pharma Inc Stifel Cowen and Company JMP Securities. Jul

Dealdoc. IPO for $49.5 million. Horizon Pharma Inc Stifel Cowen and Company JMP Securities. Jul Dealdoc IPO for $49.5 million Horizon Pharma Inc Stifel Cowen and Company JMP Securities Jul 26 2011 IPO for $49.5 million Horizon Pharma Inc Stifel Companies: Cowen and Company JMP Securities Announcement

More information

NOVOHEART HOLDINGS INC. Condensed Consolidated Interim Financial Statements. Three and six months ended December 31, 2017 and 2016.

NOVOHEART HOLDINGS INC. Condensed Consolidated Interim Financial Statements. Three and six months ended December 31, 2017 and 2016. NOVOHEART HOLDINGS INC Condensed Consolidated Interim Financial Statements Three and six months ended December 31, 2017 and 2016 (Unaudited) Condensed Consolidated Interim Statement of Financial Position

More information

Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited Neuren Pharmaceuticals Limited ABN 72 111 496 130 Appendix 4D Half year report Neuren Pharmaceuticals Limited Appendix 4D Half-Year Financial Report Name of entity Neuren Pharmaceuticals Limited 30 June

More information

PENSION & BENEFITS! T he cross-border transfer of employees can have A BNA, INC. REPORTER

PENSION & BENEFITS! T he cross-border transfer of employees can have A BNA, INC. REPORTER A BNA, INC. PENSION & BENEFITS! REPORTER Reproduced with permission from Pension & Benefits Reporter, 36 BPR 2712, 11/24/2009. Copyright 2009 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

More information

Life Sciences Spotlight Effectively Treating the Impacts of the Converged Revenue Recognition Model

Life Sciences Spotlight Effectively Treating the Impacts of the Converged Revenue Recognition Model Issue 4, March 2012 Life Sciences Spotlight Effectively Treating the Impacts of the Converged Revenue Recognition Model In This Issue: Background Key Accounting Issues Challenges for Life Sciences Entities

More information

UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC.

UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE, INC. CONSOLIDATED FINANCIAL STATEMENTS WITH SUPPLEMENTARY INFORMATION YEARS ENDED JUNE 30, 2015 AND 2014 WITH INDEPENDENT AUDITOR S REPORT CONSOLIDATED FINANCIAL STATEMENTS WITH SUPPLEMENTARY INFORMATION YEARS

More information

AVIATION PRACTICE GROUP February 2018

AVIATION PRACTICE GROUP February 2018 AVIATION PRACTICE GROUP February 2018 New Tax Law Affects the Purchase and Operation of New or Used Aircraft The 2017 Tax Cuts and Jobs Act (the Act) significantly affects business aviation. The full impact

More information

The Section 367(d) Paradox: Peering into the Abyss from a Safe Distance

The Section 367(d) Paradox: Peering into the Abyss from a Safe Distance The University of Chicago Law School 67 th Annual Federal Tax Conference November 7, 2014 The Section 367(d) Paradox: Peering into the Abyss from a Safe Distance Presentation By: Eric B. Sensenbrenner

More information

GOVERNMENT OF PUERTO RICO DEPARTMENT OF THE TREASURY. Regulation to implement the provisions of Section 2101, 2102, 2103 and 2104 of

GOVERNMENT OF PUERTO RICO DEPARTMENT OF THE TREASURY. Regulation to implement the provisions of Section 2101, 2102, 2103 and 2104 of GOVERNMENT OF PUERTO RICO DEPARTMENT OF THE TREASURY Regulation to implement the provisions of Section 2101, 2102, 2103 and 2104 of Act No. 120 of October 31, 1994, as amended, known as the Puerto Rico

More information

CHAPTER Section 1 of P.L.1997, c.349 (C.54:10A-5.28) is amended to read as follows:

CHAPTER Section 1 of P.L.1997, c.349 (C.54:10A-5.28) is amended to read as follows: CHAPTER 14 AN ACT providing credits against certain taxes for investing in New Jersey emerging technology businesses, and amending P.L.1997, c.349, and supplementing chapter 4 of Title 54A of the New Jersey

More information

Shindengen Electric Manufacturing Co., Ltd.

Shindengen Electric Manufacturing Co., Ltd. Consolidated Financial Highlights FY2013 FY2014 FY2015 FY2016 FY2017 Net sales 104,564 108,255 98,110 92,688 92,177 Operating profit 11,313 7,673 799 5,238 6,853 Ordinary profit 10,960 7,861 405 4,739

More information

Combined Financial Statements (UNAUDITED) NATIONAL MULTIPLE SCLEROSIS SOCIETY NATIONAL HEADQUARTERS, FAST FORWARD AND CHAPTERS

Combined Financial Statements (UNAUDITED) NATIONAL MULTIPLE SCLEROSIS SOCIETY NATIONAL HEADQUARTERS, FAST FORWARD AND CHAPTERS Combined Financial Statements (UNAUDITED) NATIONAL MULTIPLE SCLEROSIS SOCIETY NATIONAL HEADQUARTERS, FAST FORWARD AND CHAPTERS UNAUDITED Page 1 National Headquarters, Fast Forward and Chapters TABLE OF

More information

Combined Financial Statements (UNAUDITED) NATIONAL MULTIPLE SCLEROSIS SOCIETY NATIONAL HEADQUARTERS, FAST FORWARD AND CHAPTERS

Combined Financial Statements (UNAUDITED) NATIONAL MULTIPLE SCLEROSIS SOCIETY NATIONAL HEADQUARTERS, FAST FORWARD AND CHAPTERS Combined Financial Statements (UNAUDITED) NATIONAL MULTIPLE SCLEROSIS SOCIETY NATIONAL HEADQUARTERS, FAST FORWARD AND CHAPTERS UNAUDITED Page 1 National Headquarters, Fast Forward and Chapters TABLE OF

More information